Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 106

Similar articles for PubMed (Select 19861897)

1.

PIK3CA in breast carcinoma: a mutational analysis of sporadic and hereditary cases.

Michelucci A, Di Cristofano C, Lami A, Collecchi P, Caligo A, Decarli N, Leopizzi M, Aretini P, Bertacca G, Porta RP, Ricci S, Della Rocca C, Stanta G, Bevilacqua G, Cavazzana A.

Diagn Mol Pathol. 2009 Dec;18(4):200-5. doi: 10.1097/PDM.0b013e31818e5fa4.

PMID:
19861897
2.

PIK3CA mutation and histological type in breast carcinoma: high frequency of mutations in lobular carcinoma.

Buttitta F, Felicioni L, Barassi F, Martella C, Paolizzi D, Fresu G, Salvatore S, Cuccurullo F, Mezzetti A, Campani D, Marchetti A.

J Pathol. 2006 Feb;208(3):350-5.

PMID:
16353168
3.

PIK3CA mutations mostly begin to develop in ductal carcinoma of the breast.

Li H, Zhu R, Wang L, Zhu T, Li Q, Chen Q, Wang H, Zhu H.

Exp Mol Pathol. 2010 Feb;88(1):150-5. doi: 10.1016/j.yexmp.2009.09.016. Epub 2009 Oct 8.

PMID:
19818761
4.

PML protein expression in hereditary and sporadic breast cancer.

Plevová P, Bouchal J, Fiurásková M, Foretová L, Navrátilová M, Zapletalová J, Curík R, Kubala O, Prokop J, Kolár Z.

Neoplasma. 2007;54(4):263-8.

PMID:
17822314
5.

Clinicopathologic analysis of breast cancers with PIK3CA mutations in Japanese women.

Maruyama N, Miyoshi Y, Taguchi T, Tamaki Y, Monden M, Noguchi S.

Clin Cancer Res. 2007 Jan 15;13(2 Pt 1):408-14. Epub 2007 Jan 3.

6.

BRCA2 mutation-associated breast cancers exhibit a distinguishing phenotype based on morphology and molecular profiles from tissue microarrays.

Bane AL, Beck JC, Bleiweiss I, Buys SS, Catalano E, Daly MB, Giles G, Godwin AK, Hibshoosh H, Hopper JL, John EM, Layfield L, Longacre T, Miron A, Senie R, Southey MC, West DW, Whittemore AS, Wu H, Andrulis IL, O'Malley FP.

Am J Surg Pathol. 2007 Jan;31(1):121-8.

PMID:
17197928
7.

Can a phenotype for recessive inheritance in breast cancer be defined?

Ellberg C, Jönsson G, Olsson H.

Fam Cancer. 2010 Dec;9(4):525-30. doi: 10.1007/s10689-010-9355-4.

PMID:
20549370
8.

[PIK3CA mutation is an independent indicator of malignant phenotype and prognosis in breast cancer].

Li SY, Wang W, Li JM, Wang Z, Wen RY, Chen J, Miao XT.

Zhonghua Zhong Liu Za Zhi. 2011 Aug;33(8):605-8. Chinese.

PMID:
22325221
9.

Pathologic characteristics of breast parenchyma in patients with hereditary breast carcinoma, including BRCA1 and BRCA2 mutation carriers.

Adem C, Reynolds C, Soderberg CL, Slezak JM, McDonnell SK, Sebo TJ, Schaid DJ, Myers JL, Sellers TA, Hartmann LC, Jenkins RB.

Cancer. 2003 Jan 1;97(1):1-11.

10.

Mutational hotspot in exon 20 of PIK3CA in breast cancer among Singapore Chinese.

Liang X, Lau QC, Salto-Tellez M, Putti TC, Loh M, Sukumar S.

Cancer Biol Ther. 2006 May;5(5):544-8. Epub 2006 May 6.

PMID:
16582596
11.

Mucinous breast carcinomas lack PIK3CA and AKT1 mutations.

Kehr EL, Jorns JM, Ang D, Warrick A, Neff T, Degnin M, Lewis R, Beadling C, Corless CL, Troxell ML.

Hum Pathol. 2012 Dec;43(12):2207-12. doi: 10.1016/j.humpath.2012.03.012. Epub 2012 Jun 15.

PMID:
22705004
12.

PI3K pathway activation in breast cancer is associated with the basal-like phenotype and cancer-specific mortality.

López-Knowles E, O'Toole SA, McNeil CM, Millar EK, Qiu MR, Crea P, Daly RJ, Musgrove EA, Sutherland RL.

Int J Cancer. 2010 Mar 1;126(5):1121-31. doi: 10.1002/ijc.24831.

PMID:
19685490
13.

Exon 20 PIK3CA mutations decreases survival in aggressive (HER-2 positive) breast carcinomas.

Lerma E, Catasus L, Gallardo A, Peiro G, Alonso C, Aranda I, Barnadas A, Prat J.

Virchows Arch. 2008 Aug;453(2):133-9. doi: 10.1007/s00428-008-0643-4. Epub 2008 Aug 5.

PMID:
18679714
14.

BRCA-associated breast cancer: absence of a characteristic immunophenotype.

Robson M, Rajan P, Rosen PP, Gilewski T, Hirschaut Y, Pressman P, Haas B, Norton L, Offit K.

Cancer Res. 1998 May 1;58(9):1839-42.

15.

CCND1 and ZNF217 gene amplification is equally frequent in BRCA1 and BRCA2 associated and non-BRCA breast cancer.

Plevova P, Cerna D, Balcar A, Foretova L, Zapletalova J, Silhanova E, Curik R, Dvorackova J.

Neoplasma. 2010;57(4):325-32.

PMID:
20429623
16.

Concomitant PI3K-AKT and p53 alterations in endometrial carcinomas are associated with poor prognosis.

Catasus L, Gallardo A, Cuatrecasas M, Prat J.

Mod Pathol. 2009 Apr;22(4):522-9. doi: 10.1038/modpathol.2009.5. Epub 2009 Feb 20.

17.

PIK3CA-AKT pathway mutations in micropapillary breast carcinoma.

Flatley E, Ang D, Warrick A, Beadling C, Corless CL, Troxell ML.

Hum Pathol. 2013 Jul;44(7):1320-7. doi: 10.1016/j.humpath.2012.10.018. Epub 2013 Jan 24.

PMID:
23352210
18.

Phosphatidylinositol-3-kinase and AKT1 mutations occur early in breast carcinoma.

Dunlap J, Le C, Shukla A, Patterson J, Presnell A, Heinrich MC, Corless CL, Troxell ML.

Breast Cancer Res Treat. 2010 Apr;120(2):409-18. doi: 10.1007/s10549-009-0406-1. Epub 2009 May 6.

PMID:
19418217
19.

PIK3CA mutations in advanced ovarian carcinomas.

Wang Y, Helland A, Holm R, Kristensen GB, Børresen-Dale AL.

Hum Mutat. 2005 Mar;25(3):322.

PMID:
15712344
20.

The PIK3CA gene is mutated with high frequency in human breast cancers.

Bachman KE, Argani P, Samuels Y, Silliman N, Ptak J, Szabo S, Konishi H, Karakas B, Blair BG, Lin C, Peters BA, Velculescu VE, Park BH.

Cancer Biol Ther. 2004 Aug;3(8):772-5. Epub 2004 Aug 26. Erratum in: Cancer Biol Ther. 2005 Feb;4(2):133.

PMID:
15254419
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk